1st Quarter - Report
BIOGEN for BIOGEN
Firm
Client
Income
—
Expenses
$200,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Initiatives to create comparative effectiveness studies within the Medicare program -- supporting increased transparency/reporting requirements.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate Appropriations Committee |
| KATHLEEN TREGONING | Staff, Senate Budget Committee |
Copyright/Patent/Trademark CPT
Patent Reform -- S. 1145 and HR 1908 provisions related to apportionment of damages, inequitable conduct, and post-grant/second window.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate Appropriations Committee |
| KATHLEEN TREGONING | Staff, Senate Budget Committee |
Health Issues HCR
Follow on Biologics, including HR 1956, HR 1038, and HR 5629. Generating support for Committee/House consideration.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate Appropriations Committee |
| KATHLEEN TREGONING | Staff, Senate Budget Committee |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.